CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach to fight cancers. This approach consists of …
promising immunotherapeutic approach to fight cancers. This approach consists of …
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells
F Meng, S Zhang, J Xie, Y Zhou, Q Wu, B Lu… - Journal of Hematology & …, 2023 - Springer
Background The cytotoxicity of NK cells is largely dependent on IgG Fc receptor CD16a,
which mediates antibody-dependent cell-mediated cytotoxicity (ADCC). The high-affinity and …
which mediates antibody-dependent cell-mediated cytotoxicity (ADCC). The high-affinity and …
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy
M Chehelgerdi, F Behdarvand Dehkordi… - Molecular Cancer, 2023 - Springer
The advent of iPSCs has brought about a significant transformation in stem cell research,
opening up promising avenues for advancing cancer treatment. The formation of cancer is a …
opening up promising avenues for advancing cancer treatment. The formation of cancer is a …
Engaging stemness improves cancer immunotherapy
Intra-tumoral immune cells promote the stemness of cancer stem cells (CSCs) in the tumor
microenvironment (TME). CSCs promote tumor progression, relapse, and resistance to …
microenvironment (TME). CSCs promote tumor progression, relapse, and resistance to …
Current progress of CAR-NK therapy in cancer treatment
Z Pang, Z Wang, F Li, C Feng, X Mu - Cancers, 2022 - mdpi.com
Simple Summary Chimeric antigen receptor (CAR)-T and-natural killer (NK) therapies are
promising in cancer treatment. CAR-NK therapy gains great attention due to the lack of …
promising in cancer treatment. CAR-NK therapy gains great attention due to the lack of …
New cell sources for CAR-based immunotherapy
M Mazinani, F Rahbarizadeh - Biomarker Research, 2023 - Springer
Chimeric antigen receptor (CAR) T cell therapy, in which a patient's own T lymphocytes are
engineered to recognize and kill cancer cells, has achieved striking success in some …
engineered to recognize and kill cancer cells, has achieved striking success in some …
NK cell-based immunotherapy in colorectal cancer
M Della Chiesa, C Setti, C Giordano, V Obino… - Vaccines, 2022 - mdpi.com
Human Natural Killer (NK) cells are all round players in immunity thanks to their powerful
and immediate response against transformed cells and the ability to modulate the …
and immediate response against transformed cells and the ability to modulate the …
[HTML][HTML] DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy
L Cifaldi, O Melaiu, R Giovannoni… - Frontiers in …, 2023 - frontiersin.org
DNAM-1 is a major NK cell activating receptor and, together with NKG2D and NCRs, by
binding specific ligands, strongly contributes to mediating the killing of tumor or virus …
binding specific ligands, strongly contributes to mediating the killing of tumor or virus …
[HTML][HTML] Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: lessons from phase 3 trials. An expert panel opinion from the American …
MA Perales, LD Anderson Jr, T Jain… - … and cellular therapy, 2022 - Elsevier
ABSTRACT Since 2017, 3 CD19-directed chimeric antigen receptor (CAR) T cell therapies—
axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel—have been …
axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel—have been …